Doctors prescribe peptides constantly — insulin, semaglutide, and teriparatide are all peptides. What many decline to prescribe are unapproved research peptides, and the reasons are structural: no trial-grade evidence, no legal supply chain, and personal liability for anything that goes wrong with a compound no regulator has reviewed.
The evidence standard mainstream medicine runs on
Before a therapy enters routine practice, clinicians expect randomized controlled trial data with enough participants and follow-up to characterize both benefit and harm. The peptides doctors do prescribe cleared that bar. Semaglutide's STEP 1 trial randomized 1,961 adults and found 14.9% mean weight loss versus 2.4% with placebo over 68 weeks (NEJM 2021) — alongside systematic adverse-event tracking that fed directly into the drug's label.
Compounds like BPC-157 or TB-500 have nothing comparable: their literature is mostly animal studies, with no adequately powered human trials of efficacy or safety. A clinician who prescribes them is dosing humans on the strength of rodent data, which most are trained — and professionally obligated — not to do. The gap is covered in detail on the risks page.
Regulatory status: most research peptides cannot be legally supplied
The practical blocker is sharper than evidence culture: for many popular peptides, there is no lawful product to prescribe. They are not FDA-approved drugs, and when compounding pharmacies asked to make them from bulk ingredients, the FDA reviewed the nominations and placed compounds including BPC-157, CJC-1295, ipamorelin, and MOTS-c in the category of bulk substances that "may present significant safety risks" — citing immunogenicity concerns, peptide-related impurities, limited or absent human safety data, and for CJC-1295 reported serious adverse events. Category 2 substances sit outside the interim policy under which pharmacies may compound from nominated bulk ingredients while FDA review is pending — so there is no pharmaceutical-grade supply.
This is also why "doctors prescribe things off-label all the time" doesn't transfer here. Off-label prescribing means using an approved drug — manufactured to pharmaceutical standards, with a known safety profile — for an indication outside its label, and it is a normal, legal part of medicine. An unapproved research peptide has no approved product to prescribe off-label in the first place.
That leaves a prescriber with no pharmaceutical-grade source. Writing for a product that only exists as a "research use only" chemical means directing a patient to an unregulated supply chain — a step that carries obvious medicolegal exposure. Malpractice coverage, medical-board standards, and informed-consent doctrine are all built around approved or at least legally compoundable therapies; an adverse event from an unapproved peptide leaves the physician personally holding the risk.
Quality problems even at the edge of the legitimate market
Physician caution is also informed by what happened in the most regulated corner of the peptide gray zone. During the semaglutide shortage, licensed compounders sold versions of the drug — and the FDA's resulting safety communication documented adverse events including hospitalizations from dosing errors, plus products made from semaglutide sodium and acetate salt forms that are different active ingredients never evaluated for safety or effectiveness. If quality broke down there, clinicians reasonably assume anonymous research-peptide vendors are worse, not better.
What doctors do prescribe — and what that reveals
The dividing line is not peptide chemistry; it is evidence plus regulatory status. Peptide drugs with labels are prescribed at enormous scale: insulin, semaglutide and tirzepatide, teriparatide for osteoporosis, and tesamorelin for its labeled indication. When a research peptide graduates — completes trials, wins approval, enters the pharmacy supply chain — physicians prescribe it. Reluctance toward the rest is the same standard applied consistently, not hostility to peptides. Some clinics do operate in the gray zone anyway; the difference between those practices and mainstream medicine is precisely the evidence and supply-chain infrastructure described above, which is worth understanding before interpreting a doctor's "no" as ignorance.